@LightningMcQueen Novo Nordisk shares have fallen for several reasons:
Disappointing results of the drug CagriSema: Phase 3 data from the trial of the experimental anti-obesity drug CagriSema showed an average weight loss of 22.7%, below the 25% target expected by investors. This led to a loss of over 120 billion dollars in market capitalization.
Inclusion of Ozempic and Wegovy in Medicare price negotiations: The U.S. government has added Ozempic and Wegovy to the list of 15 drugs included in Medicare price negotiations. Failure to cooperate could result in penalties or exclusion from Medicare reimbursement. This caused Novo Nordisk shares to fall by 4%.
Competitive pressure: Eli Lilly, Novo Nordisk's main competitor, has seen positive results with its anti-obesity drug Zepbound, which showed an average weight loss of 23% in clinical trials. This has increased competitive pressure in the weight loss drug market.
Together, these factors have contributed to the recent decline in Novo Nordisk's share value.
